Trial Profile

A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 17 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Odronextamab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Prednisone; Rituximab; Rituximab; Vincristine
Indications Diffuse large B cell lymphoma
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms OLYMPIA-3
Sponsors Regeneron Pharmaceuticals

22 Apr 2025 Planned End Date changed from 18 Sep 2028 to 30 Apr 2029.
22 Apr 2025 Planned primary completion date changed from 18 Sep 2028 to 30 Mar 2028.
22 Apr 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com